Melanie A. Hundt, Yanhong Deng, Maria M. Ciarleglio, Michael H. Nathanson, Joseph K. Lim – 29 July 2020

Allison J. Kwong, Avegail Flores, Giovanna Saracino, Jodi Boutté, Greg McKenna, Giuliano Testa, Ranjeeta Bahirwani, Anji Wall, W. Ray Kim, Göran Klintmalm, James F. Trotter, Sumeet K. Asrani – 29 July 2020 – In the United States, centers performing liver transplant (LT) are primarily evaluated by patient survival within 1 year after LT, but tight clustering of outcomes allows only a narrow window for evaluation of center variation for quality improvement. Alternate measures more relevant to patients and the transplant community are needed.

Anja Christina Koop, Nina Doreen Thiele, David Steins, Erik Michaëlsson, Malte Wehmeyer, Ludger Scheja, Babett Steglich, Samuel Huber, Julian Schulze zur Wiesch, Ansgar W. Lohse, Jörg Heeren, Johannes Kluwe – 29 July 2020 – Myeloperoxidase (MPO) activity has been associated with the metabolic syndrome, cardiovascular and liver disease. Here, we evaluate the therapeutic potential of MPO inhibition on nonalcoholic steatohepatitis (NASH) and NASH‐induced fibrosis, the main determinant of outcomes.

Andrea D. Branch – 28 July 2020 – Coronavirus disease 2019 (COVID‐19) has created an emergency of epic proportions. While a vaccine may be forthcoming, this is not guaranteed, as discussed herein.

Andrea D. Branch – 28 July 2020 – Coronavirus disease 2019 (COVID‐19) has created an emergency of epic proportions. While a vaccine may be forthcoming, this is not guaranteed, as discussed herein.

Nikolaos Perakakis, Aditya Joshi, Natia Peradze, Konstantinos Stefanakis, Georgia Li, Michael Feigh, Sanne Skovgard Veidal, Glenn Rosen, Michael Fleming, Christos S. Mantzoros – 28 July 2020 – CHS‐131 is a selective peroxisome proliferator‐activated receptor gamma modulator with antidiabetic effects and less fluid retention and weight gain compared to thiazolidinediones in phase II clinical trials. We investigated the effects of CHS‐131 on metabolic parameters and liver histopathology in a diet‐induced obese (DIO) and biopsy‐confirmed mouse model of nonalcoholic steatohepatitis (NASH).

Yong Chun Chong, Tan Boon Toh, Zhiling Chan, Quy Xiao Xuan Lin, Dexter Kai Hao Thng, Lissa Hooi, Zhaobing Ding, Timothy Shuen, Han Chong Toh, Yock Young Dan, Glenn Kunnath Bonney, Lei Zhou, Pierce Chow, Yulan Wang, Touati Benoukraf, Edward Kai‐Hua Chow, Weiping Han – 27 July 2020 – Tumor‐specific metabolic rewiring, acquired to confer a proliferative and survival advantage over nontransformed cells, represents a renewed focus in cancer therapy development.

Dmitrij Ostroumov, Steven Duong, Jessica Wingerath, Norman Woller, Michael P. Manns, Kai Timrott, Moritz Kleine, Wolf Ramackers, Stephanie Roessler, Sven Nahnsen, Stefan Czemmel, Oliver Dittrich‐Breiholz, Tobias Eggert, Florian Kühnel, Thomas C. Wirth – 27 July 2020

Adrian Reuben – 27 July 2020

Gen‐Sheng Feng, Kaisa L. Hanley, Yan Liang, Xiaoxue Lin – 26 July 2020 – Hepatocellular carcinoma (HCC) is a most deadly malignant disease worldwide, with no effective mechanism‐based therapy available. Therefore, following the “miracle” outcomes seen in a few patients at the advanced stages of melanoma or lung cancer, the immune checkpoint inhibitors (ICIs) immediately entered clinical trials for advanced HCC patients without pre‐clinical studies.